Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal nalbuphine-hydromorphone dose combination for postoperative PCIA after gynecologic laparoscopy
ChiCTR1900024436Phase 4Recruiting
- Sponsor
- Affiliated Hospital of Inner Mongolia Medical University
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of nalbuphine and hydromorphone in postoperative pain (5 arms), sponsored by Affiliated Hospital of Inner Mongolia Medical University. Primary endpoint: VAS pain score. Started Apr 2019; status: recruiting.
02
Drugs
nalbuphinehydromorphone
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ChiCTR1900024436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024436.